Search results (10)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
MyMelanoma study selected to join NHS DigiTrials initiative
15 November 2024
Three projects – including the Oxford-led MyMelanoma study - have been selected to join an NHS initiative, which aims to sign up tens of thousands of volunteers over the next two years to help improve the diagnosis and treatment of cancer patients.
Ludwig Oxford’s Richard White receives 2023 Outstanding Research award from the Society for Melanoma Research
18 August 2023
Richard White has received the 2023 Outstanding Research award from the Society for Melanoma Research.
Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment
19 December 2022
New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
Datasets used to train AI to detect skin cancer lack information on darker skin and often incomplete
10 November 2021
Research by Oxford University Hospital academics have found the images and data available for training AI to spot skin cancer are insufficient and include very few images of darker skin.
Blood tests may predict response to immunotherapy for melanoma
4 October 2021
A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.
Higher testosterone levels in men linked to greater melanoma risk
1 April 2021
New research from Dr Eleanor Watts at the Nuffield Department of Population Health has found this association for the first time
Being a part of cancer drug discoveries
17 December 2020
Susan Cakebread, gives her account of being on the Tebentafusp experimental immunotherapy drug trial in 2014. A Phase 1 trial for melanoma that began here in Oxford, and is now entering Phase 3 trials after giving Susan back her life.
New melanoma drug a step closer to the clinic
24 November 2020
Clinical trials into the use of Tebentafusp for metastatic uveal melanoma have been conducted by the University of Oxford and Immunocore. The positive results of the most recent trial mean this drug could now be used in future treatment.
Epigenetic markers for melanoma patient response to ICB therapy
3 September 2020
Development fund winners Rosalin Cooper & Ben Fairfax are investigating the epigenetic landscape of melanoma patients and how it can impact patient sensitivity to ICB therapy
New melanoma cancer drug in development shows promise
27 August 2020
University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma